Cargando…

Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma

Despite advances in our understanding of the biology of chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), the differential diagnosis among these tumors remains one of the most problematic in renal pathology. Today, CK7 is the most recommended marker to distinguish these entities, h...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalewski, Adam, Szylberg, Łukasz, Tyloch, Janusz, Antosik, Paulina, Neska-Długosz, Izabela, Frąckowski, Łukasz, Tyloch, Dominik, Purpurowicz, Piotr, Grzanka, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815282/
https://www.ncbi.nlm.nih.gov/pubmed/30467700
http://dx.doi.org/10.1007/s12253-018-0548-8
_version_ 1783463150403715072
author Kowalewski, Adam
Szylberg, Łukasz
Tyloch, Janusz
Antosik, Paulina
Neska-Długosz, Izabela
Frąckowski, Łukasz
Tyloch, Dominik
Purpurowicz, Piotr
Grzanka, Dariusz
author_facet Kowalewski, Adam
Szylberg, Łukasz
Tyloch, Janusz
Antosik, Paulina
Neska-Długosz, Izabela
Frąckowski, Łukasz
Tyloch, Dominik
Purpurowicz, Piotr
Grzanka, Dariusz
author_sort Kowalewski, Adam
collection PubMed
description Despite advances in our understanding of the biology of chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), the differential diagnosis among these tumors remains one of the most problematic in renal pathology. Today, CK7 is the most recommended marker to distinguish these entities, however it appears insufficiently accurate by itself. This study aimed to find an easily accessible IHC stain that might out-compete CK7 in this field. Expressions of CK7, cyclin D1, p16, survivin, CD138, Ki-67 and caspase 3 (CASP3) were analyzed in a total of 27 cases (20 ROs and 7 ChRCCs). Immunoreactivity was assessed based on a combined score of the extent and intensity of staining. Compared to RO, a higher percentage of the total ChRCCs stained positive for CK7 (67% vs. 22%, respectively) and CASP3 (86% vs. 25%) (P < 0.005). The differences in staining with cyclin D1, p16, survivin, CD138 and Ki-67 turned out to be statistically insignificant in differentiating ChRCC from RO. CASP3 is a promising marker in distinguishing ChRCC from RO and may represent an alternative for CK7. Cyclin D1, p16, survivin, CD138 and Ki-67 cannot be used to distinguish these neoplasms.
format Online
Article
Text
id pubmed-6815282
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-68152822019-11-06 Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma Kowalewski, Adam Szylberg, Łukasz Tyloch, Janusz Antosik, Paulina Neska-Długosz, Izabela Frąckowski, Łukasz Tyloch, Dominik Purpurowicz, Piotr Grzanka, Dariusz Pathol Oncol Res Original Article Despite advances in our understanding of the biology of chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO), the differential diagnosis among these tumors remains one of the most problematic in renal pathology. Today, CK7 is the most recommended marker to distinguish these entities, however it appears insufficiently accurate by itself. This study aimed to find an easily accessible IHC stain that might out-compete CK7 in this field. Expressions of CK7, cyclin D1, p16, survivin, CD138, Ki-67 and caspase 3 (CASP3) were analyzed in a total of 27 cases (20 ROs and 7 ChRCCs). Immunoreactivity was assessed based on a combined score of the extent and intensity of staining. Compared to RO, a higher percentage of the total ChRCCs stained positive for CK7 (67% vs. 22%, respectively) and CASP3 (86% vs. 25%) (P < 0.005). The differences in staining with cyclin D1, p16, survivin, CD138 and Ki-67 turned out to be statistically insignificant in differentiating ChRCC from RO. CASP3 is a promising marker in distinguishing ChRCC from RO and may represent an alternative for CK7. Cyclin D1, p16, survivin, CD138 and Ki-67 cannot be used to distinguish these neoplasms. Springer Netherlands 2018-11-22 2019 /pmc/articles/PMC6815282/ /pubmed/30467700 http://dx.doi.org/10.1007/s12253-018-0548-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Kowalewski, Adam
Szylberg, Łukasz
Tyloch, Janusz
Antosik, Paulina
Neska-Długosz, Izabela
Frąckowski, Łukasz
Tyloch, Dominik
Purpurowicz, Piotr
Grzanka, Dariusz
Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma
title Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma
title_full Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma
title_fullStr Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma
title_full_unstemmed Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma
title_short Caspase 3 as a Novel Marker to Distinguish Chromophobe Renal Cell Carcinoma from Oncocytoma
title_sort caspase 3 as a novel marker to distinguish chromophobe renal cell carcinoma from oncocytoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815282/
https://www.ncbi.nlm.nih.gov/pubmed/30467700
http://dx.doi.org/10.1007/s12253-018-0548-8
work_keys_str_mv AT kowalewskiadam caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT szylbergłukasz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT tylochjanusz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT antosikpaulina caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT neskadługoszizabela caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT frackowskiłukasz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT tylochdominik caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT purpurowiczpiotr caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma
AT grzankadariusz caspase3asanovelmarkertodistinguishchromophoberenalcellcarcinomafromoncocytoma